

Etrib

Etoricoxib

COMPOSITION

Etrib 60 Tablet: Each film coated tablet contains Etoricoxib INN 60 mg.

Etrib 90 Tablet: Each film coated tablet contains Etoricoxib INN 90 mg.

PHARMACOLOGY

Etrib is a preparation of Etoricoxib. It is a non-steroidal anti-inflammatory drug (NSAID). It has anti-inflammatory, analgesic and antipyretic activities. Etoricoxib is a selective cyclooxygenase-2 (COX-2) inhibitor.

INDICATIONS

Etrib (Etoricoxib) is indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and other chronic musculoskeletal disorders, acute gout, dysmenorrhea and following dental surgery.

DOSAGE AND ADMINISTRATION

For adult and adolescent over 16 years, in osteoarthritis, chronic musculoskeletal disorders and dysmenorrhea, the recommended dose of **Etrib** (Etoricoxib) is 60 mg once daily. In rheumatoid arthritis, this dose is 90 mg once daily and in pain following dental surgery and acute gout, this dose is 120 mg once daily.

Safety and effectiveness of Etoricoxib in paediatric patients have not been established.

CONTRAINDICATIONS

It is contraindicated in patients with hypersensitivity to any component of this product, patients with inflammatory bowel disease and severe congestive heart failure.

WARNING AND PRECAUTION

In patients with advanced renal disease, treatment with Etoricoxib is not recommended. If therapy is required, close monitoring of the patient's renal function is required. Caution should also be required when initiating treatment with Etoricoxib in patients with considerable dehydration. The possibility of fluid retention, edema or hypertension should be taken into consideration when Etoricoxib is used in patients with pre-existing edema, hypertension or heart failure. Etoricoxib should be used with caution in patients who have previously experienced acute asthmatic attacks, urticaria or rhinitis, which were precipitated by salicylates or non-selective cyclooxygenase inhibitors. Caution should also be taken in patients with a prior history of gastric perforation, ulcer and bleeding and patients older than 65 years of age.

SIDE EFFECTS

Side effects of Etoricoxib includes dry mouth, taste disturbance, mouth ulcer, flatulence, constipation, appetite and weight change, chest pain, fatigue, paraesthesia, influenza-like syndrome and myalgia.

USE IN PREGNANCY AND LACTATION

Etoricoxib should be avoided in late pregnancy because it may cause premature closure of the ductus arteriosus. As it is excreted in breast milk, use of Etoricoxib should be avoided during lactation.

USE IN CHILDREN AND ADOLESCENTS

Etoricoxib is contraindicated in children and adolescents under 16 years of age.

DRUG INTERACTIONS

Oral anticoagulants, Diuretics and ACE inhibitors, Acetylsalicylic acid, Cyclosporin, Lithium, Methotrexate, Oral contraceptives, Prednisone/Prednisolone, Digoxin, Ethinyl estradiol drugs metabolized by CYP isoenzymes, Ketoconazole, Rifampicin and Antacids have interaction with Etoricoxib.

OVERDOSAGE

In the event of overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the GI tract, employ clinical monitoring and institute supportive therapy, if required.

STORAGE

Store below 30°C temperature in a cool and dry place. Protect from light and moisture. Keep out of the reach of children.

HOW SUPPLIED

Etrib 60 Tablet: Each box contains 30 tablets in Alu-PVDC blister pack.

Etrib 90 Tablet: Each box contains 30 tablets in Alu-PVDC blister pack.